Toggle Main Menu Toggle Search

Open Access padlockePrints

Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26)

Lookup NU author(s): Dr Caroline Bridgens, Professor Gareth Veal, Dr Chris RedfernORCiD, Dr Jane Renwick

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The synthesis and potent inhibitory activity of novel 3-(1H-imidazol-and triazol-1-yl)-2,2-dimethyl-3-(4-(naphthalen-2-ylamino)phenyl)propyl derivatives vs a MCF-7 CYP26A1 microsomal assay is described. This study focused on the effect of modifying the heme binding azole group and the flexible C3 chain on inhibitory activity and selectivity. The most promising inhibitor 2,2-dimethyl-3-[4-(naphthalen-2-ylamino)-phenyl]-3-[1,2,4]triazol-1-yl-propionic acid methyl ester (17) (IC50 = 0.35 nM as compared with liarozole IC50 = 540 nM and R116010 IC50 = 10 nM) was evaluated for CYP selectivity and hepatic stability. Compounds with CYP26 inhibitory IC50 values <= 50 nM enhanced the biological activity of exogenous ATRA, as evidenced by a 3.7-5.8-fold increase in CYP26A1 mRNA in SH-SY5Y neuroblastoma cells as compared with ATRA alone. All compounds demonstrated an activity comparable with or better than R116010, and the induction correlated well with CYP26 inhibition data. These studies highlight the promising activity profile of this novel CYP26 inhibitor and suggest it as an appropriate candidate for future development.


Publication metadata

Author(s): Gomaa MS, Bridgens CE, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C

Publication type: Article

Publication status: Published

Journal: Journal of Medicinal Chemistry

Year: 2011

Volume: 54

Issue: 19

Pages: 6803-6811

Print publication date: 15/08/2011

ISSN (print): 0022-2623

ISSN (electronic): 1520-4804

Publisher: American Chemical Society

URL: http://dx.doi.org/10.1021/jm200695m

DOI: 10.1021/jm200695m


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
C7735/A9612Cancer Research UK

Share